A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma
Phase II Evaluation of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma
Sponsor: Ligand Pharmaceuticals
A PHASE2 clinical study on HIV Infections and Sarcoma, Kaposi, this trial is completed. The trial is conducted by Ligand Pharmaceuticals and has accumulated 5 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ligand Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Hershey, United States
- • New Orleans, United States
- • Palm Springs, United States